Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Malawi and Tanzania launch national "provided-initiated" HIV screening:

This article was originally published in Clinica

Executive Summary

The government of Malawi is calling on the sexually-active of its population to test for HIV. The move is in response to an acknowledged lack of control of the disease and a need for better data to support prevention planning. Estimates put national prevalence at around 14% of the country's 12 million population; only 15% of the country's six million sexually-active population are thought to know their HIV status. The programme will also adopt guidance issued recently by the WHO on conducting "provider-initiated" voluntary testing, from which the patient has to actively opt out (see Clinica No 1259, p 9). Around 80% of people with HIV in sub-Saharan Africa are unaware of being infected, the WHO estimates. Tanzania, too, has just launched a national HIV-testing programme based on this guidance, Clinica understands.

You may also be interested in...

Towa Plans 10 Launches In December 2020

After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well. 

Pfizer Confirms EU Pegfilgrastim Launch Plans

Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts